Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-15T23:14:31.766Z Has data issue: false hasContentIssue false

The impact of a best practice advisory on inpatient prescribing of piperacillin-tazobactam

Published online by Cambridge University Press:  07 March 2022

Katherine L. Peterson*
Affiliation:
Division of Infectious Disease, University of Vermont Medical Center, Burlington, Vermont
Bradley J. Tompkins
Affiliation:
Department of Medicine, Larner College of Medicine at The University of Vermont, Burlington, Vermont
John W. Ahern
Affiliation:
Department of Pharmacy, University of Vermont Medical Center, Burlington, Vermont
Lindsay M. Smith
Affiliation:
Division of Infectious Disease, University of Vermont Medical Center, Burlington, Vermont
*
Author for correspondence: Katherine L. Peterson, DO, Division of Infectious Disease, University of Vermont Medical Center, 111 Colchester Avenue, Burlington, VT 05401. E-mail: Katherine.Peterson@UVMhealth.org

Abstract

Information

Type
Research Brief
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction in any medium, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Fig. 1.Interrupted time series showing defined daily dose (DDD) per 1,000 patient days of cefazolin, ceftriaxone, piperacillin-tazobactam, and meropenem before and after implementation of the best practice advisory (BPA).